Jazz Pharmaceuticals to Showcase Innovations at Upcoming Investor Events
1. Highlights of Upcoming Webcasts
On December 17, 2025, Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced its participation in two significant investor events slated for January 2026. The company, known for its commitment to developing innovative treatments for serious diseases, is gearing up for a pivotal month that will showcase its advancements in oncology and corporate strategy.
Zanidatamab HERIZON-GEA-01 Investor Webcast
Jazz Pharmaceuticals will host an investor webcast on January 9, 2026, at 6:30 a.m. PT / 3:30 p.m. GMT. This session will primarily focus on the results from the Phase 3 zanidatamab HERIZON-GEA-01 trial. The webcast will feature insights from senior management, including commentary from Dr. Geoffrey Ku, an Associate Attending physician at the prestigious Memorial Sloan Kettering Cancer Center. This event follows the oral presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on January 8, 2026, highlighting the importance of the data that will be discussed.
44th Annual J.P. Morgan Healthcare Conference
Following the zanidatamab webcast, Jazz Pharmaceuticals will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 11:15 a.m. PST / 7:15 p.m. GMT. Renee Gala, the company’s President and Chief Executive Officer, will lead the presentation, providing a comprehensive overview of the company's strategic direction and a business update. This high-profile conference is one of the most anticipated events in the healthcare investment community, making Jazz's participation particularly noteworthy.
Accessing the Presentations
Investors and interested parties can access audio webcasts of these presentations through the Investors section of Jazz Pharmaceuticals' website. The company ensures that a replay of the webcasts will be available for 30 days, allowing stakeholders to engage with the content at their convenience.
2. About Jazz Pharmaceuticals
Jazz Pharmaceuticals is a global biopharmaceutical company headquartered in Dublin, Ireland. With a mission to transform the lives of patients and their families, Jazz is dedicated to developing potentially life-changing medicines for serious diseases, particularly those with limited therapeutic options. The company boasts a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, alongside a growing array of cancer treatments.
Jazz Pharmaceuticals' commitment to a patient-focused and science-driven approach fuels its innovative research and development efforts across a robust pipeline of therapeutics in oncology and neuroscience. With facilities and personnel spread across multiple countries, Jazz is well-positioned to serve patients worldwide.
As the company prepares for these investor events, market watchers will be keen to see how the results from the zanidatamab trial and updates from the healthcare conference will influence Jazz's market position and strategic initiatives moving forward.
